PIK3CA, the gene encoding the alpha isoform of PI3K (PI3Kα), is frequently mutated and oncogenic in breast cancer. PI3Kα inhibitors are in clinical development and despite promising early clinical activity, primary and acquired resistance is frequent among patients. We have previously reported that residual downstream mTORC1 activity upon treatment with PI3Kα inhibitors drives resistance to these agents. However, the underlying mechanisms that mediate this phenotype are not fully understood. Here we show that in cancer cells resistant to PI3Kα inhibition, PDK1 blockade restores sensitivity to these therapies. SGK1, which is activated by PDK1, contributes to the maintenance of residual mTORC1 activity and cell survival through direct phosphorylation and inhibition of TSC2. Targeting either PDK1 or SGK1 prevents mTORC1 activation and restores the antitumoral effects of PI3Kα inhibition in resistant cancer cells.
|Number of pages||14|
|Early online date||21 Jul 2016|
|Publication status||Published - 8 Aug 2016|
- breast cancer
- PI3K pathway
- Targeted Therapy
- drug resistance